Duration of each part of the study for one participant:~Total study duration: Up to 57 days.~Screening: up to 28 days.~Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the first 10 days following administration).
Primary Objective:~-To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin time (aPPT) clotting assay, as well as, BIVV001 capture chromogenic Coatest FVIII activity assay~Secondary Objective:~-To assess the safety and tolerability of a single IV dose of BIVV001 in adult patients with type 2N and 3 VWD